// App-Quantinova.ai

P131 : Effectiveness and safety of vedolizumab maintenance therapy for inflammatory bowel disease: findings from a Belgian registry

Researchers

Presenter

  • E Louis

Principal Investigators

  • P Bossuyt

  • A Colard

  • A Nakad

  • D Baert

  • F Mana

  • P Caenepeel

  • S Vanden Branden

  • S Vermeire

  • F DHeygere

  • B Strubbe

  • A Cremer

  • J-C Coche

  • V Setakhr

  • F Baert

  • A Vijverman

  • J L Coenegrachts

  • F Flamme

  • A Hantson

  • K Wijnen

  • E Piters

  • G Hantsbarger

  • F Wan

  • B Jiang

  • P Dolin

Medical Centers

  • University of Liege, Liege, Belgium.

  • Saint-Luc University Hospital, Brussels, Belgium

  • Imelda Ziekenhuis, Bonheiden, Belgium

  • Hospital CHC, Liège, Belgium

  • CHwapi Notre Dame, Tournai, Belgium

  • Maria Middelares Medical Centre, Ghent, Belgium

  • UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium

  • Ziekenhuis Oost Limburg, Genk, Belgium

  • Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium

  • AZ Groeninge, Kortrijk, Belgium

  • AZ Sint Lucas, Gent, Belgium

  • Hopital Universitaire Erasme, Brussels, Belgium

  • Clinique St-Pierre, Ottignies, Belgium

  • CHU UCL Namur site Sainte Elisabeth, Brussels, Belgium

  • AZ Delta, Roeselare, Belgium

  • Hopital de la Citadelle, Liege, Belgium

  • Jessaziekenhuis, Hasselt, Belgium

  • CHU Ambroise Paré, Mons, Belgium

  • Takeda Pharmaceuticals, Medical Affairs, Brussels, Belgium

  • Takeda Pharmaceuticals Company, Statistics, Boston, USA

  • Takeda Pharmaceuticals, Epidemiology, London, UK

Locations

  • Belgium

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Genetic Disorder

  • Gastroenterology (GU)

Disease

  • Inflammatory bowel disease

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved